Clopidogrel plus aspirin in atrial fibrillation

New England Journal of Medicine

Volumn 361, Issue 13, 2009, Pages 1314-

  Shalimar, S ^a   Pangtey, Ghan Shyam ^b   Singh, Kumar Kirti ^a  

^a ALL INDIA INSTITUTE OF MEDICAL SCIENCES   (India)

^b LADY HARDINGE MEDICAL COLLEGE   (India)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; CLOPIDOGREL; CYTOCHROME P450 2C19; ISOENZYME; PROTON PUMP INHIBITOR;

CARDIOVASCULAR DISEASE; FOOD AND DRUG ADMINISTRATION; GASTROINTESTINAL HEMORRHAGE; HEART INFARCTION; HUMAN; LETTER; METABOLITE; PRIORITY JOURNAL; RISK;

ASPIRIN; ATRIAL FIBRILLATION; DRUG INTERACTIONS; DRUG THERAPY, COMBINATION; HUMANS; PLATELET AGGREGATION INHIBITORS; PROTON PUMP INHIBITORS; STROKE; TICLOPIDINE;

EID: 70349462765     PISSN: 00284793     EISSN: 15334406     Source Type: Journal    
DOI: None     Document Type: Letter

References (4)

1. Furuta T, Sugimoto M, Shirai N, Ishizaki T. CYP2C19 pharmacogenomics associated with therapy of Helicobacter pylori infection and gastro-esophageal reflux diseases with a proton pump inhibitor. Pharmacogenomics 2007;8:1199-1210 (Pubitemid 47578229)
2. Ho PM, Maddox TM, Wang L, et al. Risk of adverse outcomes associated with concomitant use of clopidogrel and proton pump inhibitors following acute coronary syndrome. JAMA 2009;301:937-944
3. Sibbing D, Morath T, Stegherr J, et al. Impact of proton pump inhibitors on the antiplatelet effects of clopidogrel. Thromb Haemost 2009;101:714-719
4. Food and Drug Administration. Early communication about an ongoing safety review of clopidogrel bisulfate (marketed as Plavix). (Accessed September 3, 2009, at http://www.fda.gov/Drugs/DrugSafety/ PostmarketDrugSafetyInformationforPatientsandProviders/ DrugSafetyInformationforHeathcareProfessionals/ucm079520.htm.)